A Study Assessing Additional Contribution Of The Combined Imaging Approach With 68Ga-DOTA-TATE And Fluorine-18 fluorodeoxyglucose (18F-FDG) Using Volumetric Parameters In Patients With Neuroendocrine Tumors (NETs).

Trial Profile

A Study Assessing Additional Contribution Of The Combined Imaging Approach With 68Ga-DOTA-TATE And Fluorine-18 fluorodeoxyglucose (18F-FDG) Using Volumetric Parameters In Patients With Neuroendocrine Tumors (NETs).

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Fludeoxyglucose F-18 (Primary) ; Gallium 68-DOTATATE (Primary)
  • Indications Neuroendocrine tumours
  • Focus Diagnostic use
  • Most Recent Events

    • 06 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top